Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Crigler–Najjar syndrome is a recessively inherited disorder characterized by severe unconjugated hyperbilirubinemia caused by a deficiency of uridine diphospho-glucuronosyl transferase 1A1. Current therapy relies on phototherapy to prevent kernicterus, but liver transplantation presently is the only permanent cure. Gene therapy is a potential alternative, and recent work has shown that helper-dependent adenoviral (HD-Ad) vectors, devoid of all viral coding sequences, induce prolonged transgene expression and exhibit significantly less chronic toxicity than early-generation Ad vectors. We used a HD-Ad vector to achieve liver-restricted expression of human uridine diphospho-glucuronosyl transferase 1A1 in the Gunn rat, a model of the human disorder. Total plasma bilirubin levels were reduced from >5.0 mg/dl to «1.4 mg/dl for >2 yr after a single i.v. administration of vector expressing the therapeutic transgene at a dose of 3 × 10 12 viral particles per kg. HPLC analysis of bile from treated rats showed the presence of bilirubin glucuronides at normal WT levels >2 yr after one injection of vector, and i.v. injection of bilirubins IIIα and XIIIα in the same animals revealed excess bilirubin-conjugating capacity. There was no significant elevation of liver enzymes (alanine aminotransferase) and only transient, moderate thrombocytopenia after injection of the vector. A clinically significant reduction in serum bilirubin was observed with a dose as low as 6 × 10 11 viral particles per kg. We conclude that complete, long-term correction of hyperbilirubinemia in the Gunn rat model of Crigler–Najjar syndrome can be achieved with one injection of HD-Ad vector and negligible chronic toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element
Donello, J. E., Loeb, J. E., & Hope, T. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.6.5085-5092.1998 · Cited by 350
Cited by
Iyanagi, T. (2007) · International Review of Cytology · doi:10.1016/s0074-7696(06)60002-8 · Cited by 290
New Insights on Adenovirus as Vaccine Vectors
Lasaro, M. O., & Ertl, H. C. (2009) · Molecular Therapy · doi:10.1038/mt.2009.130 · Cited by 263
Current Advances and Future Challenges in Adenoviral Vector Biology and Targeting
Campos, S., & Barry, M. (2007) · Current Gene Therapy · doi:10.2174/156652307780859062 · Cited by 210
“The elimination of Ad antigen expression in HD-Ad vectors permits long-term episomal expression of genes in quiescent cells by avoiding problems associated with the cellular immune response against viral gene products [Palmer & Ng, 2005, Toietta et al., 2005].”
Adenoviral Vector Immunity: Its Implications and Circumvention Strategies
S. Ahi, Y., S. Bangari, D., & K. Mittal, S. (2011) · Current Gene Therapy · doi:10.2174/156652311796150372 · Cited by 185
Pastore, N., Blomenkamp, K., Annunziata, F., Piccolo, P., Mithbaokar, P., Maria Sepe, R., Vetrini, F., Palmer, D., Ng, P., Polishchuk, E., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202046 · Cited by 142
Self-citationAdenoviral vector-based strategies against infectious disease and cancer
Zhang, C., & Zhou, D. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1165908 · Cited by 110
“cell responses, and the transgene products can be stably expressed.(92,93)”
Background
Metadata
- Authors
- Toietta, G., Mane, V. P., Norona, W. S., Finegold, M. J., Ng, P., McDonagh, A. F., Beaudet, A. L., & Lee, B.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2005-03-07
- Volume
- 102
- Issue
- 11
- Pages
- 3930-3935
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2122851326
- Cited by
- 140
- References
- 1
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.